Clinical course of COVID-19 among immunocompromised children: a clinical case series.

Autor:	El Dannan H; Pediatric Department, Shaikh Khalifa Medical City, Abu Dhabi, United Arab Emirates., Al Hassani M; Pediatric Department, Shaikh Khalifa Medical City, Abu Dhabi, United Arab Emirates., Ramsi M; Pediatric Critical Care Unit, Sheikh Khalifa Medical City, Abu Dhabi, United Arab Emirates musaab.ali@gmail.com.
Jazyk:	angličtina
Zdroj:	BMJ case reports [BMJ Case Rep] 2020 Oct 31; Vol. 13 (10). Date of Electronic Publication: 2020 Oct 31.
DOI:	10.1136/bcr-2020-237804
Abstrakt:	Infection with SARS-CoV-2 represents a great source of concern and a new threat for immunocompromised patients. Limited studies are available on COVID-19 in immunocompromised children. This case series aimed to evaluate the clinical and laboratory characteristics, management and outcomes of COVID-19 in five children immunocompromised due to different underlying conditions. All had mild symptoms or were asymptomatic at presentation. All had a benign course of illness. No changes or delays in their treatment regimens occurred, and none experienced a relapse of the original disease, developed severe COVID-19 or died. However, these cases showed a prolonged duration of virus shedding. This report suggests that immunocompromised paediatric patients may not be at a higher risk of developing severe COVID-19. However, further studies are required to elaborate on the pathogenesis of COVID-19 in this vulnerable group. Competing Interests: Competing interests: None declared. (© BMJ Publishing Group Limited 2020. No commercial re-use. See rights and permissions. Published by BMJ.)
Databáze:	MEDLINE
Externí odkaz:	Zobrazit plný text záznamu